Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
REDWOOD CITY, Calif., May 01, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be presenting at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:40 am ET being held in Las Vegas, Nevada.
The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O'Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
